Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Psychological Well‐Being and Depressive Symptoms: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

View at publisher Summarise with VIRAT
Authors: Tsung-Hsuan Hung, Chyi-Rong Chen, Chih‐Wei Hsu, Andre F. Carvalho, Brendon Stubbs, Ping‐Tao Tseng, Liang‐Jen Wang, Paul‐Yang Lin
Cited by: 0
References: 77

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for metabolic disorders. Howeve, their effects on depressive symptoms and psychological well-being remain uncertain. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of GLP-1RAs on depressive symptoms and psychological well-being. Random-effects models were used to calculate standardized mean differences (SMDs). Subgroup and meta-regression analyses were performed to explore heterogeneity. The protocol was registered with PROSPERO (CRD42024566217). RESULTS: In total, 25 trials (17,751 participants) evaluated psychological well-being and 11 trials (1961 participants) evaluated depressive symptoms. GLP-1RA treatment was associated with a small but significant improvement in psychological well-being compared with control conditions (SMD = 0.374, 95% CI 0.093-0.656), whereas no significant effect was observed for depressive symptoms (SMD = 0.079, 95% CI -0.024-0.182). Improvements in psychological well-being were consistently observed in studies using semaglutide, tirzepatide or liraglutide, subcutaneous administration, and in populations with type 2 diabetes mellitus or obesity. CONCLUSIONS: GLP-1RA treatment was associated with modest improvements in psychological well-being but not depressive symptoms. These findings should be interpreted cautiously and suggest that any observed psychological benefits are likely indirect, potentially reflecting improvements in metabolic status or general health, rather than direct mood-improving effects.

Fields of Study & Subjects

Diabetes Treatment and Management Pharmacology and Obesity Treatment Treatment of Major Depression

Publication details

Journal / source
Human Psychopharmacology Clinical and Experimental
Volume
41
Issue
3
Pages
e70041–e70041
Publication date
31 March 2026
Language
EN